{
  "success": true,
  "pagesUsed": [
    0,
    1,
    3,
    4,
    5,
    6,
    12,
    13,
    14,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Atezolizumab + Paclitaxel",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Atezolizumab 840 mg IV on Days 1 and 15 plus Paclitaxel 90 mg/m2 IV on Days 1, 8, and 15 of every 28-day cycle."
      },
      {
        "id": "arm_2",
        "name": "Placebo + Paclitaxel",
        "type": {
          "code": "Placebo Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Placebo Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Placebo IV on Days 1 and 15 plus Paclitaxel 90 mg/m2 IV on Days 1, 8, and 15 of every 28-day cycle."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Global Study",
        "instanceType": "StudyCohort",
        "characteristic": "Approximately 600 patients randomized globally"
      },
      {
        "id": "cohort_2",
        "name": "China Population",
        "instanceType": "StudyCohort",
        "characteristic": "Total of approximately 130 patients enrolled in mainland China (including those from Global study)"
      },
      {
        "id": "cohort_3",
        "name": "PD-L1-positive subpopulation",
        "instanceType": "StudyCohort",
        "characteristic": "Patients whose PD-L1 status is IC1/2/3 at the time of randomization"
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Atezolizumab + Paclitaxel - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Atezolizumab + Paclitaxel during Screening"
      },
      {
        "id": "elem_2",
        "name": "Atezolizumab + Paclitaxel - Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Atezolizumab + Paclitaxel during Treatment Period"
      },
      {
        "id": "elem_3",
        "name": "Atezolizumab + Paclitaxel - Survival Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Atezolizumab + Paclitaxel during Survival Follow-up"
      },
      {
        "id": "elem_4",
        "name": "Placebo + Paclitaxel - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo + Paclitaxel during Screening"
      },
      {
        "id": "elem_5",
        "name": "Placebo + Paclitaxel - Treatment Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo + Paclitaxel during Treatment Period"
      },
      {
        "id": "elem_6",
        "name": "Placebo + Paclitaxel - Survival Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo + Paclitaxel during Survival Follow-up"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 6,
      "cohortCount": 3,
      "elementCount": 6
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Double Blind",
        "codeSystem": "USDM",
        "decode": "Double Blind"
      },
      "maskedRoles": [
        "Subject",
        "Investigator",
        "Sponsor"
      ],
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "2:1"
      },
      "stratificationFactors": [
        "Tumour PD-L1 status (IC0 vs. IC1/2/3)",
        "Prior taxane treatment (yes vs. no)",
        "Presence of liver metastases (yes vs. no)",
        "Region"
      ],
      "controlType": {
        "code": "Placebo Control",
        "codeSystem": "USDM",
        "decode": "Placebo Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2",
        "cohort_3"
      ],
      "therapeuticAreas": [
        "Oncology",
        "Breast Cancer"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Double Blind",
        "maskedRoles": [
          "Subject",
          "Investigator",
          "Sponsor"
        ]
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "2:1",
        "stratificationFactors": [
          "Tumour PD-L1 status (IC0 vs. IC1/2/3)",
          "Prior taxane treatment (yes vs. no)",
          "Presence of liver metastases (yes vs. no)",
          "Region"
        ]
      },
      "controlType": "Placebo",
      "therapeuticAreas": [
        "Oncology",
        "Breast Cancer"
      ]
    },
    "arms": [
      {
        "name": "Atezolizumab + Paclitaxel",
        "type": "Experimental Arm",
        "description": "Atezolizumab 840 mg IV on Days 1 and 15 plus Paclitaxel 90 mg/m2 IV on Days 1, 8, and 15 of every 28-day cycle.",
        "isTitration": false,
        "doseEpochs": null
      },
      {
        "name": "Placebo + Paclitaxel",
        "type": "Placebo Comparator",
        "description": "Placebo IV on Days 1 and 15 plus Paclitaxel 90 mg/m2 IV on Days 1, 8, and 15 of every 28-day cycle.",
        "isTitration": false,
        "doseEpochs": null
      }
    ],
    "cohorts": [
      {
        "name": "Global Study",
        "characteristic": "Approximately 600 patients randomized globally"
      },
      {
        "name": "China Population",
        "characteristic": "Total of approximately 130 patients enrolled in mainland China (including those from Global study)"
      },
      {
        "name": "PD-L1-positive subpopulation",
        "characteristic": "Patients whose PD-L1 status is IC1/2/3 at the time of randomization"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Up to 28 days prior to Cycle 1 Day 1"
      },
      {
        "name": "Treatment Period",
        "description": "28-day cycles until disease progression or unacceptable toxicity"
      },
      {
        "name": "Survival Follow-up",
        "description": "Followed for survival approximately every 3 months after treatment discontinuation"
      }
    ]
  }
}